{"id":58937,"date":"2026-03-06T16:01:04","date_gmt":"2026-03-06T08:01:04","guid":{"rendered":"https:\/\/flcube.com\/?p=58937"},"modified":"2026-03-06T16:01:05","modified_gmt":"2026-03-06T08:01:05","slug":"merck-kgaa-reports-e21-1-billion-2025-sales-healthcare-drives-3-7-organic-growth-amid-currency-headwinds","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58937","title":{"rendered":"Merck KGaA Reports \u20ac21.1\u202fBillion 2025 Sales \u2013 Healthcare Drives 3.7% Organic Growth Amid Currency Headwinds"},"content":{"rendered":"\n

Merck KGaA<\/strong> (ETR: MRK<\/a>) announced fiscal year 2025 results<\/strong>, recording \u20ac21.102\u202fbillion<\/strong> (~$24.5\u202fbillion) in net sales with 3.1% organic growth<\/strong>, offset by \u20133.7% foreign exchange drag<\/strong> from U.S. dollar and Asian currency weakness. The Healthcare division<\/strong> delivered solid 3.7% organic growth<\/strong> to \u20ac8.6\u202fbillion<\/strong>, with SpringWorks acquisition<\/strong> contributing 2.2% portfolio effect<\/strong> and all franchises recording positive momentum.<\/p>\n\n\n\n

Group Financial Summary<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>Change<\/th>Commentary<\/th><\/tr><\/thead>
Net Sales<\/strong><\/td>\u20ac21.102\u202fbn (~$24.5\u202fbn)<\/td>+3.1% organic<\/strong><\/td>Operational strength across divisions<\/td><\/tr>
Reported Growth<\/strong><\/td>\u20130.3%<\/td>FX impact<\/td>USD\/Asia currency translation headwinds<\/td><\/tr>
FX Impact<\/strong><\/td>\u20133.7%<\/td>Negative<\/td>Strong euro vs. USD and Asian currencies<\/td><\/tr>
2026 Guidance<\/strong><\/td>\u20ac20.0\u201321.1\u202fbn<\/td>\u20131% to +2% organic<\/strong><\/td>Conservative outlook amid macro uncertainty<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Healthcare Division Performance<\/h2>\n\n\n\n

Division Total:<\/strong> \u20ac8.6\u202fbillion (+3.7% organic<\/strong>, +2.2% portfolio effect from SpringWorks)<\/p>\n\n\n\n

Franchise<\/th>2025 Organic Growth<\/th>Key Products & Performance<\/th><\/tr><\/thead>
Rare Diseases<\/strong><\/td>New (portfolio effect)<\/td>Ogsiveo<\/strong> (desmoid tumors), Gomekli\/Ezmekly<\/strong> (NF1 plexiform neurofibromas), pimicotinib<\/strong> (TGCT); SpringWorks integration driving 2026 growth outlook<\/td><\/tr>
Cardiovascular, Metabolism & Endocrinology (CM&E)<\/strong><\/td>+7.3%<\/strong><\/td>Largest growth driver; Glucophage<\/strong> \u20ac975\u202fM (+2.3%), Concor<\/strong> \u20ac625\u202fM (+2.4%), Euthyrox<\/strong> \u20ac653\u202fM (+5.4%), Saizen<\/strong> \u20ac388\u202fM (+6.2%)<\/td><\/tr>
Neurology & Immunology (N&I)<\/strong><\/td>+1.9%<\/strong><\/td>Mavenclad<\/strong> \u20ac1.2\u202fbn (+16.6%<\/strong>), North America\/Europe demand; Rebif<\/strong> \u201323.0% (expected decline)<\/td><\/tr>
Oncology<\/strong><\/td>+0.3%<\/strong><\/td>Erbitux<\/strong> +6.6% (China resilience); Bavencio<\/strong> \u201313.8% (urothelial competition)<\/td><\/tr>
Fertility<\/strong><\/td>+0.4%<\/strong><\/td>Pergoveris<\/strong> +22.6% (strong global); Gonal-f<\/strong> \u20136.7% (portfolio shift)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Portfolio Highlights<\/h2>\n\n\n\n
Asset<\/th>Indication<\/th>Status<\/th>Revenue Impact<\/th><\/tr><\/thead>
Ogsiveo<\/strong> (nirogacestat)<\/td>Desmoid tumors<\/td>Acquired via SpringWorks; Q3 2025 launch<\/td>Rare Diseases franchise anchor<\/td><\/tr>
Gomekli\/Ezmekly<\/strong> (mirdametinib)<\/td>NF1 plexiform neurofibromas<\/td>Approved; global rights<\/td>Pediatric\/adult orphan indication<\/td><\/tr>
Pimicotinib<\/strong><\/td>Tenosynovial giant cell tumor (TGCT)<\/td>Late-stage development<\/td>2026 growth catalyst<\/td><\/tr>
Mavenclad<\/strong><\/td>Relapsing multiple sclerosis<\/td>Market expansion<\/td>\u20ac1.2\u202fbn run-rate; MS portfolio transition from Rebif<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regional & Competitive Dynamics<\/h2>\n\n\n\n